modelPegvisomant
Extends from Pharmacolibrary.Drugs.ATC.H.H01AX01.
Information
| name: | Pegvisomant | |
| ATC code: | H01AX01 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 7.6 | L |
| clearance: | 36 | mL/h/kg |
| other parameters in model implementation | ||
Pegvisomant is a genetically engineered growth hormone receptor antagonist used in the treatment of acromegaly, a disorder caused by excessive secretion of growth hormone, usually due to pituitary adenoma. It is a pegylated protein administered via subcutaneous injection. Pegvisomant is approved for clinical use for acromegaly in numerous countries.
Pharmacokinetics
Pharmacokinetic parameters reported in adult patients with acromegaly following subcutaneous administration; healthy volunteers and both sexes included in original studies.
References
Muto, C, et al., & Suwa, T (2011). Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in asian and Western acromegaly patients. Journal of clinical pharmacology 51(12) 1628–1643. DOI:10.1177/0091270010386954 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21209237
Yang, LP, & Keating, GM (2010). Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70(13) 1745–1769. DOI:10.2165/11204510-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20731479
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)